Press Release Liestal, Switzerland, May 20, 2010 – Santhera Pharmaceuticals (SIX: SANN) announced today that its MICONOS Phase III study evaluating Catena®/Sovrima® for the treatment of Friedreich’s Ataxia missed its primary endpoint. Trends towards improvement in the key neurological endpoint were however identified by a meta-analysis of all Santhera’s Phase...
Some relevant information about Catena® (Idebenon) Catena®: Fact Sheet Catena®(idebenone): Product Monograph Catena®(idebenone): Product Monograph. Part III Actual Payer Coverage in Canada for CATENA® (Idebenon) Santhera Pharmaceuticals about preliminary results of the CATENA US clinical trial
News Release Liestal, Switzerland, July 24, 2008 – Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia. Health Canada’s decision is the first marketing authorization worldwide for any Friedreich’s Ataxia therapy....
In July 1999, Mrs. Nicole St-Jean of the Canadian Association of Friedreich’s Ataxia asked me for an article concerning hearing problems related to this disease. The presence of hearing problems in persons afflicted with Friedreich’s ataxia is misunderstood. One knows better the dominant symptoms leading to the diagnosis such as...
Around 90% of patients afflicted with Friedreich’s Ataxia (FA) eventually show cardiac symptoms. In general, ataxia precedes the beginning of the cardiac symptoms. With most patients, it involves a cardiac disease called left ventricular hypertrophy. Left ventricular hypertrophy is an increase in the thickness of the wall and of the...
Friedreich’s ataxia is a hereditary genetic disease. A gene (a segment of a chromosome) which is defective is its cause. This gene is found on chromosome 9. The FA gene, like all other genes, contains the information for the building of a protein (a sequence of amino acids) which is...
